On January 21, the Phase I clinical research launch meeting of the MVA strain monkeypox live attenuated vaccine independently developed by Sinopharm Group China National Biotec Group Shanghai Institute of Biological Products was held at the Henan Provincial Infectious Disease Hospital (Zhengzhou Sixth People's Hospital). The launch meeting was fully trained and discussed around the clinical trial plan, key points and difficulties of clinical site operations.

On September 9, 2024, this monkeypox vaccine obtained the clinical trial notification issued by the State Food and Drug Administration. It is the first monkeypox vaccine approved for clinical trials in my country and is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in my country.
On January 22, the first batch of subjects in the Phase I clinical trial of the MVA strain monkeypox live attenuated vaccine were enrolled, marking that my country's first monkeypox vaccine officially entered the clinical trial stage. This clinical trial will fully evaluate the safety and immunogenicity of the vaccine in different populations and accumulate more clinical support data for the vaccine to be marketed.

In 2024, WHO once again announced that the monkeypox epidemic constituted an "international public health emergency." In January 2025, my country reported the first cluster outbreak of monkeypox virus clade Ib strain.

Vaccination with monkeypox vaccine is an important measure to prevent the spread of monkeypox virus. Shanghai Institute of Biological Products will work with researchers and related parties to accelerate the clinical research and marketing of the vaccine to better meet my country's major health and public safety needs in responding to monkeypox epidemic prevention and control.

https://finance.eastmoney.com/